Introduction: Androgen deprivation therapy is the mainstay treatment for patients with
prostate cancer who are not candidates for definitive treatment, are diagnosed with …

The last 25 years have witnessed an unprecedented rise in the number of men given a
diagnosis of prostate cancer. This has been a major consequence from the clinical …

INTRODUCTION The Prouts Neck Meetings on Prostate Cancer began in 1985 through the
efforts of the Organ Systems Branch of the National Cancer Institute to stimulate new …

Recent advances in genomics technology have led to the massive discovery of new drug
targets for prostate cancer; however, none of the currently available therapeutics is curative …

Purpose: Stemming from its inherent heterogeneity, single-agent treatments are essentially
ineffective against castration-resistant prostate cancer (CRPC). Thus, clinically relevant …

Clearly, no neoplasm other than prostate cancer has benefited from so many breakthroughs
since the beginning of this decade: the past two years can be considered exceptional due to …

Prostate cancer remains one of the leading causes of cancer death in men worldwide. In the
past decade, several new treatments for advanced prostate cancer have been approved …

Prostate cancer (PCa), the most common, non-cutaneous male malignancy (1), is primarily
driven by androgen signaling. Thus, clinical management of the disseminated disease is …

Castrate-resistant prostate cancer (CRPC), the most life-threatening form of prostate cancer,
has recently been the focus of many successful new treatments. Contemporary trials …